SCHEMBL2014362

SCHEMBL2014362

O=C(CN[C@@H](C(=O)O)c1ccccc1)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MAPK1 P28482 1/20 0.51
ATM Q13315 1/20 0.51
CTSL P07711 1/20 0.47
CTSS P25774 1/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
GAA P10253 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
ABCC3 O15438 1/20 0.44
NR1I2 O75469 1/20 0.44
ABCB11 O95342 1/20 0.44
NR3C1 P04150 1/20 0.44
RARG P13631 1/20 0.44
CNR1 P21554 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29045009 0.84 ALDH1A1 (0.54) ALDH1A1L3MBTL1MAPK1KMT2AMEN1
SCHEMBL21959864 0.82 MMP9 (0.54) ALDH1A1L3MBTL1MAPK1ATMCYP1A2
SCHEMBL381081 0.80 ALDH1A1 (0.53) ALDH1A1L3MBTL1MAPK1ATMKMT2A
SCHEMBL15902594 0.80 ALDH1A1 (0.53) ALDH1A1L3MBTL1MAPK1ATMKMT2A
SCHEMBL10832272 0.80 ALDH1A1 (0.56) ALDH1A1L3MBTL1MAPK1ATMKMT2A
SCHEMBL22424808 0.79 ALDH1A1 (0.51) ALDH1A1L3MBTL1MAPK1CTSLCTSS
SCHEMBL21555767 0.79 ALDH1A1 (0.51) ALDH1A1L3MBTL1MAPK1KMT2AMEN1
SCHEMBL19749931 0.79 ALDH1A1 (0.51) ALDH1A1L3MBTL1MAPK1KMT2AMEN1
Hydrochloric Acid SCHEMBL6988925 0.78 ALDH1A1 (0.47) ALDH1A1L3MBTL1MAPK1CTSLCTSS
Hydrochloric Acid SCHEMBL10832268 0.78 ALDH1A1 (0.54) ALDH1A1L3MBTL1MAPK1ATMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964730-B2 Amino-substituted ethylamino β2 adrenergic receptor agonists THERAVANCE, INC. (US) 2011-06-21 US disclosed
US-20090111850-A1 Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-04-30 US disclosed
EP-1687257-B1 AMINO-SUBSTITUTED ETHYLAMINO BETA2 ADRENERGIC RECEPTOR AGONISTS THERAVANCE INC (US) 2009-04-15 EP disclosed
US-7399863-B2 Amino-substituted ethylamino β2 adrenergic receptor agonists THERAVANCE, INC. (US) 2008-07-15 US disclosed
US-20050113411-A1 Amino-substituted ethylamino beta2 adrenergic receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111850-A1 Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists ADRB2, ADRB1, ADRA2A ALDH1A1 989/4885L3MBTL1 3605/4885MAPK1 2640/4885
US-20050113411-A1 Amino-substituted ethylamino beta2 adrenergic receptor agonists ADRB2, ADRB1, ADRA2A ALDH1A1 989/4885L3MBTL1 3605/4885MAPK1 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.